INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Correct inhaler technique is key to long-term treatment success

Before commencing treatment with Bronchitol® (mannitol), all patients should be assessed for bronchial hyperresponsiveness to inhaled mannitol during administration of their initiation dose.1

The Bronchitol Initiation Dose Assessment (BIDA) must be passed before any patients start treatment with Bronchitol. Patients must be pre-medicated with a bronchodilator 5-15 minutes before the BIDA is started.

UK healthcare professionals should also refer to the Risk Minimisation Material and can download our UK Electronic BIDA Sheet.

The BIDA must be given under the supervision of an experienced cystic fibrosis healthcare professional trained to:

  • Monitor oxygen saturation (SpO2)
  • Perform spirometry
  • Manage acute bronchospasm, including appropriate use of resuscitation equipment

The BIDA is to assess hyperresponsiveness to mannitol.It also creates an opportunity to teach patients the correct inhaler technique and how to identify a productive cough, which can contribute to sputum clearance.1,2

 


1. Bronchitol® Summary of Product Characteristics. Available online at https://www.medicines.org.uk/emc/product/4085/smpc. Accessed December 2019.
2. Bilton D, et al. Eur Respir J 2011; 38: 1071-1080.
3. Flume PA, et al. Breathe 2015; 11(1): 39-48.